Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study

INTRODUCTION: The serotonin 5-HT(4) receptor agonist prucalopride is approved in the European Union for the treatment of chronic constipation. This offered the unique opportunity to include real-world observational data on cardiovascular safety in the new drug application for approval of prucaloprid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilsenan, Alicia, Fortuny, Joan, Cainzos-Achirica, Miguel, Cantero, Oscar F., Flynn, Robert W. V., Garcia-Rodriguez, Luis, Harding, Abenah, Kollhorst, Bianca, Karlsson, Pär, Linnér, Love, MacDonald, Thomas M., Odsbu, Ingvild, Plana, Estel, Ruigómez, Ana, Schink, Tania, Ziemiecki, Ryan, Andrews, Elizabeth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739451/
https://www.ncbi.nlm.nih.gov/pubmed/31134512
http://dx.doi.org/10.1007/s40264-019-00835-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739451/
https://www.ncbi.nlm.nih.gov/pubmed/31134512
http://dx.doi.org/10.1007/s40264-019-00835-0

Ejemplares similares